Search
Imidafenacin
go.drugbank.com/drugs/DB09262InvestigationalImidafenacin is an antispasmodic agent with anticholinergic effects. It antagonizes muscarinic receptors in the bladder to reduce the frequency of urination in the treatment of overactive bladder. … It is marketed in Japan under the tradenames Staybla by Ono Pharmaceutical and Uritos by Kyojin Pharmaceutical.
Products: URITOS TABLETS 0.1 MG, URITOS (TABLETS 0.1 MG)ZEN-012
go.drugbank.com/drugs/DB06042ExperimentalZEN-012 also expresses additional modes of action such as pro-apoptotic and anti-angiogenic properties. It is developed for the treatment of solid tumors. … ZEN-012 is a novel small molecule and the first anti-cancer drug in development involving two mechanisms of action: tubulin and topoisomerase II inhibition.
JSM 6427
go.drugbank.com/drugs/DB06139InvestigationalIt has been biologically validated for therapeutic use in the prevention and treatment of wet AMD, the leading cause of blindness in people over the age of 55.
Mazindol
go.drugbank.com/drugs/DB00579ApprovedIt inhibits uptake of catecholamines and blocks the binding of cocaine to the dopamine uptake transporter. … Mazindol is only approved in the United States for the treatment of Duchenne muscular dystrophy, and is not marketed or available in the United States for use in the treatment of obesity.
Adrafinil
go.drugbank.com/drugs/DB08925ApprovedWithdrawnIt was marketed in France and elsewhere in Europe under the trade name Olmifon until September 2011 when France's FDA equivalent reassessed the drug and withdrew marketing permission. … It is also been used off-label to prevent fatigue or falling asleep for extended periods of time. Adrafinil does not currently have FDA approval and is thus unregulated in the United States.
PRO 2000
go.drugbank.com/drugs/DB05385InvestigationalPRO 2000 is an investigational medicine that is not yet approved by the FDA for use outside of clinical trials. … It is being studied for the prevention of HIV infection and other sexually transmitted diseases.
Categories: Compounds used in a research, industrial, or household settingDefactinib
go.drugbank.com/drugs/DB12282ApprovedInvestigational[L53208,A273943] Defactinib was approved by the US FDA in May 2025 in a co-package alongside [avutometinib] (called Avmapki Fakzynja) for the treatment of recurrent KRAS-mutated low-grade serous ovarian … signal transduction pathways, including those involving RAS/MEK/ERK and PI3K/Akt, and its upregulation is a key resistance mechanism to MAPK inhibitors, facilitating tumor cell proliferation and survival in
Synonyms: N-methyl-4-[[4-[[3-[methyl(methylsulfonyl)amino]pyrazin-2-yl]methylamino]-5-(trifluoromethyl)pyrimidin-2-yl]amino]benzamidePhenoxybenzamine
go.drugbank.com/drugs/DB00925ApprovedInvestigationalAn alpha-adrenergic antagonist with long duration of action. It has been used to treat hypertension and as a peripheral vasodilator.
Products: Dibenzyran 10 mg KapselnGlucose-6-Phosphate
go.drugbank.com/drugs/DB03581ExperimentalIt is a normal constituent of resting muscle and probably is in constant equilibrium with fructose-6-phosphate. (Stedman, 26th ed) … An ester of glucose with phosphoric acid, made in the course of glucose metabolism by mammalian and other cells.
1-Palmitoyl-2-oleoyl-sn-glycero-3-(phospho-rac-(1-glycerol))
go.drugbank.com/drugs/DB11331ApprovedWithdrawnPalmitoyloleoyl-phosphatidylglycerol was a component of Surfaxin, discontinued in 2017, which acted as a surfactant [FDA Label].
Synonyms: 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphoglycerol, 1-Palmitoyl-2-oleoyl-sn-glycero-3-phosphatidylglycerolSalts: 1-palmitoyl-2-oleoyl-sn-glycero-3-(phospho-rac-(1-glycerol)), sodium salt